Maximizing research impact via insightful peer-review
Oncotarget’s rising popularity is due to insightful, constructive, punctual, multiple peer-review: helping our authors to increase the impact of their research
Members of Editorial Board Carlo M. Croce (former Editor-in-Chief of Cancer Research) and Andrew Schally (Nobel Prize winner)have published 27 and 10 papers in Oncotarget
Oncotarget sponsors Gordon Research Conference.
See more on Oncotarget in global News
Oncotarget is accepting papers on topics beyond oncology: Neuroscience, Endocrinology, Cardiology, Metabolism, Cell Biology, Pharmacology (all areas) and more
Impact factor (IF) Thomson Reuters JCR
FORECAST: Our preliminary analysis of the Web of Science Core Collection (1/23/17), shows that there is a potential rise in the Thomson Reuters 2016 Impact Factor for Oncotarget coming in summer of 2017
2015/2016: 5-Year Impact Factor: 5.415
Scopus/SJR ranking: 2011-ongoing: Q1 (highest rank). All years Q1 in Medicine (subject area) and Oncology
Oncotarget ranks number 1 on Total Documents (2015) among all journals in Oncology, see here
If your paper was mistakenly rejected by other leading journals, you may submit it to Oncotarget together with peer-reviews obtained from the other journal and rebuttal letter.
The term "oncotarget" encompasses all molecules, pathways, and cellular functions common in cancer and aging, neurodegeneration and atherosclerosis, lymphocytes and neurons, cancer cells and microbes.
Oncotarget is a multidisciplinary traditional journal with free-access. Oncotarget publishes papers online in weekly issues. Each issue or paper can be printed for special demand.
Our mission is to make scientific results rapidly and widely available. To maximize the impact of research via insightful review. To allow exceptional discoveries to be shared quickly. To eliminate the border between specialties. To link different fields of biomedical science. To foster applications of basic and clinical science to fight disease.
Under the leadership of the most prominent scientists, the journal helps all researchers contribute to the progress of science. Life without disease is our ultimate goal.
The success of Oncotarget has prompted us to launch sections beyond oncology.
100 Plus Papers from the Editorial Board:
See full list
Copyright © 2017 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC